US Stock MarketDetailed Quotes
FBLG FibroBiologics
- 2.195
- -0.165-6.99%
Trading Dec 30 13:32 ET
76.08MMarket Cap-4.19P/E (TTM)
2.360High2.100Low71.29KVolume2.350Open2.360Pre Close156.47KTurnover0.28%Turnover RatioLossP/E (Static)34.66MShares55.00052wk High27.78P/B55.57MFloat Cap1.07852wk Low--Dividend TTM25.32MShs Float55.000Historical High--Div YieldTTM11.02%Amplitude1.078Historical Low2.194Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
FibroBiologics Stock Forum
FibroBiologics Announces $25 Million Financing
Monday, 23rd December at 7:55 am
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (th...
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
FibroBiologics (Nasdaq: FBLG) has filed a patent application for methods using fibroblasts and Tissue Factor-expressing cells to prevent IBMIR-mediated blood clotting in cell therapy treatments. The technology aims to address a major challenge in cell therapy by reducing inflammatory and coagulative...
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
FibroBiologics (Nasdaq: FBLG) reported promising results from its artificial thymus organoid program. The technology demonstrated that fibroblasts and thymus-derived cell organoids can maintain functionality for over 50 days after transplantation, showing vascularization and generating diverse mature T cells in animal models. The organoids produced fully mature T cells with various diff...
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
According to the EMH, it is impossible to consistently outperform the market by employing strategies such as technical or fundamental analysis. The hypothesis argues that since all relevant information is already reflected in stock prices, it is not possible to gain an advantage and generate abnormal returns through stock picking or market timing. ...
$Primega Group (PGHL.US)$
$FibroBiologics (FBLG.US)$
$OrangeKloud Technology (ORKT.US)$
Last month was a good one.
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
FibroBiologics (Nasdaq: FBLG) has filed a patent application for an adhesive bandage using fibroblast cell-based technology for wound healing. This innovative approach aims to leverage the healing properties of fibroblasts in a stable, room-temperature bandage suitable for post-surgical and retail use. The company, which focuses on...
No comment yet